Janssen Biotech Inc.

04/12/2019 | Press release | Distributed by Public on 04/12/2019 16:53

BALVERSA™ (erdafitinib) Receives U.S. FDA Approval for the Treatment of Patients with Locally Advanced or Metastatic Urothelial Carcinoma with Certain FGFR Genetic Alterations